SingleBioregulators

Pinealon 20mg

Synthetic CNS bioregulator tripeptide (EDR) investigated in preclinical models for neuroprotective, epigenetic, and antioxidant properties.

Mechanism

Pinealon is hypothesized to penetrate cellular compartments and interact with chromatin structures to modulate gene expression pathways governing neuronal survival and antioxidant defenses.

Dosing

Preclinical investigation protocols frequently initiate administration at 200 mcg once daily, titrating gradually up to 500 mcg daily over experimental periods.

Reconstitution

Reconstituting a 20 mg vial with 3.0 mL of bacteriostatic water produces a clear working solution with a concentration of approximately 6.67 mg/mL (6,667 mcg/mL).

Storage

Store the lyophilized peptide powder frozen at -20 °C, and once reconstituted, maintain the vial refrigerated between 2 °C and 8 °C protected from light without refreezing.

Mix & measure Pinealon 20mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Pinealon 20mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration6.67mg/mL

Draw volume0.030mL

On the syringe3.00units

Total doses in vial: 100.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–2	200 mcg (1× daily)	3 units (0.03 mL)
Weeks 3–4	300 mcg (1× daily)	4.5 units (0.045 mL)
Weeks 5–6	400 mcg (1× daily)	6 units (0.06 mL)
Weeks 7–12	500 mcg (1× daily)	7.5 units (0.075 mL)

Reconstitution Steps

1
Draw exactly 3.0 mL of bacteriostatic water using a sterile syringe.
2
Gently inject the diluent down the inside glass wall of the Pinealon vial to prevent agitation.
3
Carefully swirl or roll the vial until the lyophilized cake is fully dissolved, avoiding shaking.
4
Label the vial with reconstitution date and store between 2 °C and 8 °C away from light.

Supplies Needed

Peptide Vial

Lyophilized Pinealon 20 mg target compound

Insulin Syringes (U-100)

Calibrated 1 mL syringes for precise microgram-level measurement

Bacteriostatic Water

Sterile diluent containing 0.9% benzyl alcohol for peptide solubilization

Alcohol Swabs

Antiseptic preparation of vial septums and injection surfaces

Why researchers study it

Neuronal protection against hypoxia and oxidative stress

Cognitive processing and memory retention models

Epigenetic regulation of cellular senescence

Free-radical mitigation and DNA preservation

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Pinealon is a synthetic tripeptide consisting of the amino acid sequence glutamic acid, aspartic acid, and arginine (Glu-Asp-Arg, or EDR). Developed as part of the Khavinson short-chain peptide bioregulator family, often referred to as cytogens, it was engineered to model regulatory mechanisms within central nervous system and pineal tissues. In preclinical literature, these low-molecular-weight peptides are hypothesized to engage directly with cellular chromatin and modulate transcription pathways involved in cellular longevity and resilience. Preclinical research primarily focuses on Pinealon's capacity to shield neuronal networks from oxidative damage, metabolic exhaustion, and hypoxic injury. While animal and in vitro models suggest improvements in cellular survival and cognitive markers, Western clinical validation remains absent. Furthermore, documented human explorations historically employed oral routes, leaving parenteral regimens strictly within the realm of experimental laboratory modeling. In laboratory protocols, Pinealon is commonly investigated over multi-week research cycles to observe progressive neuronal signaling shifts. Due to its unapproved status, research handling mandates rigorous aseptic methods, calibrated reconstitution procedures, and controlled microgram-level administration across experimental timelines.

References

1.Khavinson et al., Peptides and Ageing, 2002 — Foundational review of short-peptide bioregulators including EDR
2.PubChem, CID 154888, 2005 — Chemical identity and structure of the synthetic tripeptide Glu-Asp-Arg
3.Khavinson et al., Neuroprotective Effects of EDR, 2011 — Preclinical exploration of neuroprotective and antioxidant actions of Pinealon
4.Russian Clinical Registry, TBI Study, 2014 — Small-cohort trial investigating oral Pinealon in traumatic brain injury sequelae